1. Home
  2. NEXR vs PFSA Comparison

NEXR vs PFSA Comparison

Compare NEXR & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexera Technologies Ltd Ordinary Shares

NEXR

Nexera Technologies Ltd Ordinary Shares

HOLD

Current Price

$0.32

Market Cap

953.3K

ML Signal

HOLD

Logo Profusa Inc.

PFSA

Profusa Inc.

HOLD

Current Price

$0.76

Market Cap

902.5K

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXR
PFSA
Founded
2021
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
953.3K
902.5K
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NEXR
PFSA
Price
$0.32
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 6.9M
1.8M
Earning Date
08-14-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.70
52 Week High
$5.28
$51,750.00

Technical Indicators

Market Signals
Indicator
NEXR
PFSA
Relative Strength Index (RSI) 21.91 36.15
Support Level $0.23 N/A
Resistance Level $1.72 $1.35
Average True Range (ATR) 0.11 0.15
MACD -0.02 0.23
Stochastic Oscillator 0.82 9.33

Price Performance

Historical Comparison
NEXR
PFSA

About NEXR Nexera Technologies Ltd Ordinary Shares

Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: